Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPX-004
- Development stage
- Preclinical
- Lead developer
- Hepyx
01
Overview
HPX-004 is an undisclosed therapeutic candidate currently under development by Hepyx. As of early 2024, the company has not publicly revealed the specific molecular target, modality, or primary clinical indication for this asset. Hepyx is a biotechnology company primarily focused on developing treatments for advanced liver diseases, such as acute-on-chronic liver failure (ACLF), by targeting systemic inflammation and impaired hepatocyte proliferation. HPX-004 represents an expansion of the company's pipeline beyond its lead candidate, HPX-001, which is a combination therapy targeting TLR4 and G-CSF.
- Other names
- HPX-004-HepyxHPX004-HepyxHPX 004-Hepyx
02
Targets
GPX4 (Glutathione peroxidase 4)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on HPX-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPX-004.